Theralase Technologies Inc News

Theralase(R) Expands Clinical Team

TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and devel

AccesswireMay 2 07:00 ET

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the resear

AccesswireApr 24 07:00 ET

Theralase(R) Granted Canadian Cancer Vaccine Patent

TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and dev

AccesswireApr 5 07:00 ET

Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q4 2023 Earnings Conference

The following is a summary of the Theralase Technologies Inc. (TLTFF) Q4 2023 Earnings Call Transcript:Financial Performance:Theralase Technologies reported a 6% YoY decrease in sales to $1.07 million

moomoo AIApr 3 13:30 ET · Conference Call

Theralase(R) Release's 4Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and de

AccesswireMar 27 07:00 ET

Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association

TORONTO, ON / ACCESSWIRE / March 26, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and deve

AccesswireMar 26 07:00 ET

Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease

TORONTO, ON / ACCESSWIRE / February 12, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and

AccesswireFeb 12 07:00 ET

Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and

AccesswireFeb 8 07:00 ET

Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / February 5, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and

AccesswireFeb 5 16:35 ET

Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study

Stockhouse Jan 15 07:00 ET

Theralase Release's 3Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and

AccesswireNov 29, 2023 18:30 ET

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / November 29, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and

AccesswireNov 29, 2023 16:35 ET

Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units

Theralase Technologies (TLT.V) on Friday said it is raising up to C$1.5 million in a private placement of share units as it "mutually terminated a Listed Issuer Financing Exemption (LIFE) with Researc

MT NewswiresNov 17, 2023 16:38 ET

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and

AccesswireNov 17, 2023 16:30 ET

Theralase(R) Announces Brokered LIFE Financing

TORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and

AccesswireOct 23, 2023 17:55 ET

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study

Post Study II Monitoring of Response, Optional Maintenance Study II Treatments and Central Pathology Laboratory Review OptimizedTORONTO, ON / ACCESSWIRE / October 23, 2023 / Theralase Technologies Inc

AccesswireOct 23, 2023 07:00 ET

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)

TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the r

AccesswireSep 29, 2023 07:00 ET

Theralase(R) Grants Stock Options

TORONTO, ON / ACCESSWIRE / September 21, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research an

AccesswireSep 21, 2023 16:35 ET

Theralase(R) Closes Private Placement Equity Financing

Stockhouse Sep 7, 2023 04:30 ET

Theralase Technologies First-Half Loss Narrows Even as Revenue Declined by 23%

Theralase Technologies (TLT.V) on Tuesday said its first-half loss narrowed despite a 23% drop in revenue as it cut research and development spending. The company, which is developing light-activated

MT NewswiresAug 29, 2023 16:55 ET